Nature research paper: A serpin–myeloid axis in pancreatic cancer heterogeneity and immune evasion go.nature.com/4r3Zwdv

Pulling out all the stops vs pancreatic cancer. The recent FDA-approved, celebrated drug daraxonrasib, increased median survival by 6.5 months @RevMedicines That's a positive step but clearly not enough. This new @Cancer_Cell paper lays out a path for more. cell.com/cancer-cell/fulltex…

Excited to share our story on how SERPINs orchestrate local immunosuppressive niches in PDAC. Now out @Nature ! Spearheaded by @ChiaraFalcomata @Brown_lab1 @MiriamMerad @IcahnMountSinai @SinaiImmunol nature.com/articles/s41586-0… (1/n)

Cancer-derived SERPINE1 and SERPINB2 are local spatial organizers of immune suppression @Nature @IcahnMountSinai @ChiaraFalcomata @SinaiImmunol nature.com/articles/s41586-0…

Pancreatic tumors are highly heterogeneous and immunosuppressive. But is immune resistance imposed across the whole tumor - or built locally by distinct cancer-cell states? I’m incredibly excited to share our new paper, now out in @Nature! 🎉 doi.org/10.1038/s41586-026-1… (1/7)

Amazing news today, culmination of years of research & clinical trials in #PancreaticCancer. The @RevMedicines approval for Rasonque (Daraxonrasib) will open many doors, including other inhibitors in this space & combinations. @OncoAlert @KRASKickers fda.gov/news-events/press-an…

Honored to receive an #ERC Advanced Grant! EvokePDAC will reveal how #PancreaticCancer evades immunity and combine myeloid reprogramming with RASi to trigger antitumor immunity. Thanks to our team & collaborators! PhD & postdoc positions available—apply! erc.europa.eu/news-events/ne…

🚀 Excited to share Cellpin for #SpatialTranscriptomics! Led by P. Putze & D. Lucarelli with @fabian_theis. Outperforms 6 methods for gene prediction, scales to atlas-size references, and boosts cell-state resolution in full-transcriptome Atera data. doi.org/10.64898/2026.06.02.…

EMA fast tracks review of a medicine for metastatic #PancreaticCancer The medicine, no surprise, is Daraxonrasib. ema.europa.eu/en/news/ema-fa…

It was such a great conference-so much that patients families Need to know about keen to help them understand what this might mean for them there is so much Hope for better outcomes for a better future #sethslegacy

The @CR_UK #PanConf26 was proof how much great science is happening in #PancreaticCancer in the UK & rest of Europe. Now is the time for greater international collaborations with our partners across the Atlantic. Really enjoyed my time in London! Thanks to @BristiBasu8 for 📸

The inaugural #CRUK #PanConf26 may be over but I suspect it will not be the last one…😉 And this is thanks to all the people that made this happen, especially @TaraMcKay20, our 350+ attendees (>60% from outside the UK) and my wonderful co-organizers @Aiims1742 and @SaurLab!

Ready to start Day 2 of the inaugural @CR_UK #PancreaticCancer conference! Thanks to co-organizers @BiffiGiulia & @SaurLab, and the @CRUKresearch team for putting this wonderful meeting together. The conference hashtag is #PanConf26 @TaraMcKay20 @lgoodbu

Wow! Standing room only! Amazing to see the full house at the inaugural @CR_UK #PancreaticCancer meeting. @ciacobu delivering her keynote lecture. Thanks to all the attendees for their enthusiasm. @BiffiGiulia @SaurLab @TaraMcKay20

🎉 Day 1 of the inaugural #CRUK #PancreaticCancer conference is here 🎉 Thank you to @Aiims1742 @SaurLab @TaraMcKay20 and our session chairs for help shaping a fantastic programme!

The overall survival curves for Daraxonrasib in 2nd line advanced #PancreaticCancer leave no doubt how impactful this advance is for the field & for patients. Congratulations Brian Wolpin, @EileenMOReilly & @md_oberstein et al. A seminal #ASCO26 plenary! nejm.org/doi/full/10.1056/NE…

Catalogue entries for more than 100 antibodies sold by the research services and supply company Thermo Fisher Scientific contain images that have apparently been manipulated, according to a pair of science sleuths. go.nature.com/4wZqGEE

🎉 Very happy to have had the opportunity to contribute to this latest @DiseasePrimers #Review on #PancreaticCancer together with a number of great colleagues! @ednacukierman @EileenMOReilly @SaurLab @BarbaraGrnwald ... Hope it is a useful read! 😊💜 nature.com/articles/s41572-0…

Phoenix 🐦‍🔥 works zero-shot (out-of-the-box) on unseen cohorts, patients, organs, and tissues — no fine-tuning needed. This is the start of a real shift in how we'll use pathology archives. Hypothesis generation at this scale opens up questions we couldn't realistically ask before, especially in understudied tissues and subtypes.

Very timely @DiseasePrimers article on #PancreaticCancer given all the "buzz" about advances in this disease last few weeks. nature.com/articles/s41572-0…